Orlando, FLNCT07793929Now EnrollingIRB Ready

End Stage Renal Disease Clinical Trial in Orlando, FL

Access cutting-edge end stage renal disease treatment through this phase 1 clinical trial at a research site in Orlando. Study-provided care at no cost to qualified participants.

Sponsored by Kailera

Quick Self-Assessment

See if you qualify for this Orlando location

Preparing your pre-screening questions…

Expert Care in Orlando

Access end stage renal disease specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related end stage renal disease treatment provided free

Apply for This Orlando Location

Check if you qualify for this end stage renal disease clinical trial in Orlando, FL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Orlando

    Convenient for FL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Orlando site if eligible
  4. 4Begin participation

About This End Stage Renal Disease Study in Orlando

The primary objective of the study is to estimate the PK parameters of ribupatide in participants with severe renal impairment or end-stage kidney disease (ESKD) after a single dose of ribupatide subcutaneous (SC) injection compared with participants with normal renal function.

Sponsor: Kailera

Who Can Participate

Inclusion Criteria

Body mass index ≥18.5 at Screening.
Female Participants: Must not be pregnant or planning to be pregnant or breastfeeding or planning to breastfeed during the study and for at least 35 days after the study drug dose.
Female participants: Must have a negative serum pregnancy test at Screening.
Suitable venous access for blood sampling.

Exclusion Criteria

History or presence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, psychiatric, or neurological disease/disorder, including any acute illness, within the past 3 months determined by the Investigator (or delegate) to be clinically relevant.
Abnormal thyroid-stimulating hormone at Screening.
Any history of malignant disease including in situ cervical or prostate cancer within the last 5 years.
History of or positive test results at the Screening Visit for human immunodeficiency virus (HIV) or hepatitis B surface antigen, or active hepatitis C virus (HCV) infection.
Participated in another clinical study of a study drug or investigational device within 30 days or 5 half-lives of the study drug (whichever is longer) prior to Screening.
Received treatment with semaglutide, tirzepatide, glucagon-like peptide-1 receptor (GLP-1R) agonist, GLP-1R/glucose-dependent insulinotropic polypeptide receptor (GIPR) agonist, or glucagon receptor agonist within 3 months prior to Screening.
Known hypersensitivity to the study drug, glucagon-like peptide-1 (GLP-1) therapies, or any of the study drug ingredients.
Received any vaccinations within 30 days prior to Screening.
Current infection that requires systemically absorbed antibiotic, antifungal, antiparasitic, or antiviral medication within 10 days prior to the dose of study drug.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Orlando?

Yes, this clinical trial (NCT07793929) has an active research site in Orlando, FL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

End Stage Renal Disease Treatment Options in Orlando, FL

If you're searching for end stage renal disease treatment options in Orlando, FL, this clinical trial (NCT07793929) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Orlando research site is actively enrolling participants for this phase 1 clinical trial. You'll receive care from experienced end stage renal disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all end stage renal disease clinical trials near you to find additional studies recruiting in your area.

More Ankylosing Spondylitis Trials in Orlando, FL

See all ankylosing spondylitis clinical trials recruiting in Orlando — not just this study.

Browse Ankylosing Spondylitis Trials in Orlando →

Browse More Trials by Condition

Ankylosing Spondylitis TrialsChronic Kidney Disease TrialsAll Conditions →

Ready to Join in Orlando?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Orlando, FL